Our mission is to develop curative T cell immunotherapies for the treatment of solid tumors. A major barrier to successful T cell therapies for solid tumors is the so-called “T cell exhaustion”: during a protracted battle with tumor cells, T cells can become fatigued and are no longer able to function properly and to fight tumor cells efficiently. To overcome this challenge, our vision is to generate antitumor T cells refractory to terminal differentiation and dysfunction by developing microRNA-based synthetic circuits capable of rewiring the transcriptional programs driving T cell exhaustion.
VISION & MISSION
LEFT: An exhausted T cell (grey) failing to attack a cancer cell (yellow).
RIGHT: A reprogrammed T cell with T-FITNESS technology (blue) fighting a cancer cell (yellow).